The Usefulness of a Smartphone App–Based Smoking Cessation Program for Conventional Cigarette Users, Heated Tobacco Product Users, and Dual Users: Retrospective Study
Journal of Medical Internet Research · 2023
DOI: 10.2196/42776 ↗At a glance
Journal article in Journal of Medical Internet Research, 2023. Written by Yuko Noda and 4 co-authors. Institution: Department of Biomedical Informatics, CureApp Institute, Karuizawa, Japan. Major MEDLINE topics: Smoking Cessation, Mobile Applications, Tobacco Products, Tobacco Use Disorder. Cited 8 times so far (Crossref); 31 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Heated tobacco products (HTPs) are widespread in Japan, and smoking cessation of such products has become an important issue owing to the spread of harmful effects from HTPs. The efficacy of online digital therapy has been reported in smoking cessation treatment; however, we have limited evidence of online smoking cessation programs for HTP users.
Objective
In this study, we evaluate the usefulness of the Ascure program for HTP users (defined as exclusive HTP use or dual use of HTP and cigarettes) compared with exclusive cigarette users.
Methods
This was a retrospective study. We recruited adult smokers participating in the Ascure online smoking cessation program in Japan from June 2019 to February 2021. The Ascure smartphone app provided four elements: (1) educational video tutorials to enhance the understanding of nicotine dependence, (2) a personalized to-do list for behavior change, (3) a digital diary for record keeping, and (4) interactive chat sessions for relief from cravings or withdrawal symptoms. The primary outcome was the continuous abstinence rate (CAR) at weeks 21 to 24, biochemically validated using salivary cotinine testing. We considered those who dropped out of the program as smoking cessation failures. We analyzed the primary outcome using inverse probability weighting against tobacco product type estimated by multinomial propensity scores. We also assessed CAR at weeks 9 to 12 and program adherence.
Results
We analyzed data from 2952 participants, including 52% (1524/3478) in the cigarette group, 35% (1038/3478) in the HTP group, and 13% (390/3478) in the dual-use group, who had a mean age of 43.4 (SD 10.8) years and included 17% (513/2952) women. CAR at weeks 21 to 24 showed that exclusive HTP users were more likely to stop tobacco use than exclusive cigarette smokers (CAR 52.6% for cigarette users vs CAR 64.8% for HTP users; odds ratio [OR] 1.17, 95% CI 1.12-1.22; P
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Biomedical Informatics, CureApp Institute, Karuizawa, Japan.
- Department of Transdisciplinary Sciences for Innovation, Kanazawa University, Kanazawa, Japan.
- CureApp Inc, Tokyo, Japan.
- Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
- Tokyo Foundation for Policy Research, Toyko, Japan.
- Innovative Clinical Research Center, Kanazawa University, Kanazawa, Japan.
ORCID profiles: Yuko Noda, Ryuhei So, Misaki Sonoda, Takahiro Tabuchi, Akihiro Nomura
Cite
APA
Noda, Y., So, R., Sonoda, M., Tabuchi, T., & Nomura, A. (2023). The Usefulness of a Smartphone App–Based Smoking Cessation Program for Conventional Cigarette Users, Heated Tobacco Product Users, and Dual Users: Retrospective Study. Journal of Medical Internet Research. https://doi.org/10.2196/42776
Vancouver
Noda Y, So R, Sonoda M, Tabuchi T, Nomura A. The Usefulness of a Smartphone App–Based Smoking Cessation Program for Conventional Cigarette Users, Heated Tobacco Product Users, and Dual Users: Retrospective Study. Journal of Medical Internet Research. 2023. doi:10.2196/42776
BibTeX
@article{Noda2023,
author = {Noda, Yuko and So, Ryuhei and Sonoda, Misaki and Tabuchi, Takahiro and Nomura, Akihiro},
title = {The Usefulness of a Smartphone App–Based Smoking Cessation Program for Conventional Cigarette Users, Heated Tobacco Product Users, and Dual Users: Retrospective Study},
journal = {Journal of Medical Internet Research},
year = {2023},
doi = {10.2196/42776}
}
EUVIMED